methyl 4-(4-((tert-butoxycarbonyl)amino)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylate | 292070-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: methyl 4-(4-((tert-butoxycarbonyl)amino)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylate
• 英文别名: methyl 1-methyl-4-[[1-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]imidazole-2-carbonyl]amino]pyrrole-2-carboxylate
• CAS: 292070-58-7
• 化学式: C₁₇H₂₃N₅O₅
• 分子量: 377.4
• InChiKey: JZEOXKVBLODCGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  117
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  methyl 4-(4-((tert-butoxycarbonyl)amino)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylate 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 5.0h， 生成 4-(4-((tert-butoxycarbonyl)amino)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylic acid
  参考文献：
  名称：

  DNA序列选择性发夹式聚酰胺铂络合物的合成。

  摘要：

  已通过不同方法合成了两种含有吡咯和咪唑杂环的DNA序列选择性发夹式聚酰胺铂（II）复合物。通过固相合成制备了对（A / T）GGG（A / T）DNA序列具有选择性的六环复合物，而对（A / T）CCTG（A / T）具有选择性的八环复合物DNA序列是通过使用标准的湿化学法制得的。固相合成比湿法合成具有更高的收率，更少的纯化且更有效。因此，这是进行进一步工作的首选方法。金属配合物通过（1）H和（195）Pt NMR光谱法和ESI质谱法表征。这两种化合物为合成包含多个发夹和/或铂基的更复杂分子提供了基础。

  DOI：

  10.1002/chem.200601486
• 作为产物：
  描述：

  4-[[(1,1-二甲基乙氧基)羰基]氨基]-1-甲基-1H-吡咯-2-羧酸甲酯 在 4-二甲氨基吡啶 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.5h， 生成 methyl 4-(4-((tert-butoxycarbonyl)amino)-1-methyl-1H-imidazole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  DNA序列选择性发夹式聚酰胺铂络合物的合成。

  摘要：

  已通过不同方法合成了两种含有吡咯和咪唑杂环的DNA序列选择性发夹式聚酰胺铂（II）复合物。通过固相合成制备了对（A / T）GGG（A / T）DNA序列具有选择性的六环复合物，而对（A / T）CCTG（A / T）具有选择性的八环复合物DNA序列是通过使用标准的湿化学法制得的。固相合成比湿法合成具有更高的收率，更少的纯化且更有效。因此，这是进行进一步工作的首选方法。金属配合物通过（1）H和（195）Pt NMR光谱法和ESI质谱法表征。这两种化合物为合成包含多个发夹和/或铂基的更复杂分子提供了基础。

  DOI：

  10.1002/chem.200601486

文献信息

• [EN] METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE<br/>[FR] PROCÉDÉS ET COMPOSÉS POUR LE TRAITEMENT D'UNE MALADIE GÉNÉTIQUE
  申请人：DESIGN THERAPEUTICS INC

  公开号：WO2021158707A1

  公开（公告）日：2021-08-12

  The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

  本公开涉及化合物和方法，用于调节dmpk的表达，并治疗dmpk发挥积极作用的疾病和病况。该化合物可以是一种转录调节分子，具有第一末端、第二末端和寡聚骨架，其中：a）第一末端包括一种DNA结合基团，能够非共价结合到核苷酸重复序列CAG或CTG；b）第二末端包括结合到调节分子的蛋白结合基团，该调节分子调节包含核苷酸重复序列CAG或CTG的基因的表达；c）寡聚骨架包括连接第一末端和第二末端的连接物。
• Total Synthesis of Distamycin A and 2640 Analogues:  A Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity
  作者：Dale L. Boger、Brian E. Fink、Michael P. Hedrick

  DOI：10.1021/ja994192d

  日期：2000.7.1

  solution-phase synthesis of distamycin A and its extension to the preparation of 2640 analogues are described. Thus, solution-phase synthesis techniques with reaction workup and purification employing acid/base liquid−liquid extractions were used in the multistep preparation of distamycin A (8 steps, 40% overall yield) and a prototypical library of 2640 analogues providing intermediates and final products that

  描述了远霉素 A 的液相合成的发展及其对 2640 类似物制备的扩展。因此，采用酸/碱液-液萃取进行反应后处理和纯化的液相合成技术用于多步制备偏霉素 A（8 步，40% 总产率）和 2640 类似物的原型库，提供中间体和最终产品在常规反应规模上纯度≥95%。公开了一种简单、快速和高通量的 DNA 结合亲和力筛选的补充开发，该筛选基于来自预结合溴化乙锭置换的荧光损失，适用于评估对 DNA 均聚物或特定序列的相对或绝对结合亲和力。发夹寡核苷酸）。使用发夹寡核苷酸，
• Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease
  申请人：Howard Philip Wilson

  公开号：US20080214525A1

  公开（公告）日：2008-09-04

  A compound of formula (I); or a salt or solvate thereof, wherein: the dotted line indicates the optional presence of a double bond between C2 and C3; R 2 is selected from —H, —OH, =0, ═CH 2 , —CN, —R, OR, halo, ═CH—R, O—SO 2 —R, CO 2 R and COR; R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo, where R and R′ are independently selected from optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups; R 10 and R 11 either together form a double bond, or are selected from H and YR Y , where Y is selected from O, S and NH and R is H or C 1-7 alkyl or H and SO x M, where x is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; each X is independently a heteroarylene group; n is from 1 to 6; and R E is C 1-4 alkyl. The compound is useful for the treatment of proliferative diseases.

  化合物的公式（I）；或其盐或溶剂化物，其中：虚线表示C2和C3之间的双键是可选的；R2选择自-H，-OH，=0，═CH2，-CN，-R，OR，卤基，═CH-R，O-SO2-R，CO2R和COR；R7选择自H，R，OH，OR，SH，SR，NH2，NHR，NRR'，硝基，Me3Sn和卤基，其中R和R'独立选择自可选取代的C1-7烷基，C3-20杂环基和C5-20芳基基团；R10和R11要么一起形成双键，要么选择自H和YRY，其中Y选择自O，S和NH，R为H或C1-7烷基或H和SOxM，其中x为2或3，M为一价的药用可接受阳离子；每个X独立地是杂芳基基团；n为1至6；以及RE为C1-4烷基。该化合物可用于治疗增殖性疾病。
• WO2007/39752
  申请人：——

  公开号：——

  公开（公告）日：——
• An Extended Pyrrolobenzodiazepine–Polyamide Conjugate with Selectivity for a DNA Sequence Containing the ICB2 Transcription Factor Binding Site
  作者：Federico Brucoli、Rachel M. Hawkins、Colin H. James、Paul J. M. Jackson、Geoff Wells、Terence C. Jenkins、Tom Ellis、Minal Kotecha、Daniel Hochhauser、John A. Hartley、Philip W. Howard、David E. Thurston

  DOI：10.1021/jm4001852

  日期：2013.8.22

  The binding of nuclear factor Y (NF-Y) to inverted CCAAT boxes (ICBs) within the promoter region of DNA topoisomerase II alpha results in control of cell differentiation and cell cycle progression. Thus, NF-Y inhibitory small molecules could be employed to inhibit the replication of cancer cells. A library of pyrrolobenzodiazepine (PBD) C8-conjugates consisting of one PBD unit attached to tri-heterocyclic polyamide fragments was designed and synthesized. The DNA-binding affinity and sequence selectivity of each compound were evaluated in DNA thermal denaturation and DNase I footprinting assays, and the ability to inhibit binding of NF-Y to ICB1 and ICB2 was studied using an electrophoretic mobility shift assay (EMSA). 3a was found to be a potent inhibitor of NF-Y binding, exhibiting a 10-fold selectivity for an ICB2 site compared to an ICB1-containing sequence, and showing low nanomolar cytotoxicity toward human tumor cell lines. Molecular modeling and computational studies have provided details of the covalent attachment process that leads to formation of the PBD-DNA adduct, and have allowed the preference of 3a for ICB2 to be rationalized.